Companion Diagnostics Market

Companion Diagnostics Market (Indication: Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Companion Diagnostics Market Outlook 2028

  • The global market was valued at US$ 5.24 Bn in 2020
  • It is estimated to expand at a CAGR of 9% from 2021 to 2028
  • The global companion diagnostics market is expected to reach the value of US$ 9.30 Bn by the end of 2028

Analysts’ Viewpoint on Global Market Scenario

The global companion diagnostics industry is expected to witness tremendous growth opportunities due to rising incidences of oncology and chronic disorders across the globe. Several companion diagnostics market players are leveraging lucrative revenue opportunities. Companion diagnostics are used to identify the response of oncology patients to the targeted drug therapy. This helps in developing personalized medicine for cancer patients. However, the lengthy and complicated approval process and the equally prolonged time to develop companion diagnostics are impacting the growth of the global market. Furthermore, the unavailability of reimbursement policies in some regions is also projected to hamper market growth.

COVID-19 Impact on Global Companion Diagnostics Market

The coronavirus pandemic has put intense pressure on the global healthcare system. With a shortage of hospital beds, medical staff, and necessary protective equipment required for elective surgical processes, healthcare practitioners gave priority to critical patients suffering from severe health complications. Considering the risk and safety of patients, non-emergency diagnostic and treatment procedures have been canceled or postponed in the time of the rapidly spreading coronavirus. This factor has negatively affected the global market for companion diagnostics as cancer surgeries have also been canceled. Clinical trials in oncology have also been affected by the coronavirus. However, the market is booming after the significant efforts taken by governments, healthcare practitioners, and market stakeholders to recover from losses caused due to pandemic.

Request a sample to get extensive insights into the Companion Diagnostics Market

Increasing Prevalence of Chronic Disorders Fueling Market Growth

Rising incidences of HIV, thalassemia, colorectal cancer, melanoma, breast cancer, gastric cancer, and lung cancer is driving the demand for companion diagnostics procedures. There is a growing demand for companion diagnostic tests for the early detection and screening of chronic diseases. These tests also help reduce the side effects of drugs, improve patient outcomes, provide high diagnostic accuracy and specificity, reduce pharmacotherapy variability, and identify the most effective targeted therapy options. They are also associated with higher drug development success. The global market is booming due to the increasing demand for personalized medicines. Rising incidences of cancer and reduction in the cost of developing drugs are also having a positive impact on the global companion diagnostics market. Companion diagnostics tests and procedures help bring about better decisions with respect to treatment.

To understand how our report can bring a difference to your business strategy, Ask for a brochure

Rising Awareness of Breast Cancer Globally

Growing incidences of breast cancer across the globe are one of the key factors accelerating the global market for companion diagnostics, thereby creating value-grab opportunities for market contributors. Increasing awareness of breast cancer and the focus of health practitioners on its treatment is accelerating the global companion diagnostics market growth. However, the lung cancer segment is also generating substantial revenues in the global market. Rising pollution, unhealthy food, smoking, and chewing tobacco are mainly responsible for lung cancer, which results in the maximum number of deaths worldwide. It is particularly prevalent in low-income nations. This, alongside the development of numerous companion diagnostics and biomarkers for lung cancer, is mainly boosting the market growth. Companion diagnostics enable healthcare professionals to understand the side effects and potential risks posed by a particular therapeutic product. This eventually helps in fine-tuning treatment procedures.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Companion Diagnostics Market

North America to Lead Companion Diagnostics Industry

North America is expected to account for a major market share of the global companion diagnostics market. The rising affordability of treatment and well-established healthcare infrastructure are driving the global market for companion diagnostics in the region. The increasing prevalence of chronic diseases all over the world demand companion diagnostics procedures. A large number of ongoing clinical trials, outsourcing services, research activities, and increasing healthcare investment by governments are some of the factors responsible for the growth of the market in North America. Moreover, the significant presence of manufacturers is fueling the expansion of the North American companion diagnostics industry. Asia Pacific and Latin America are other attractive companion diagnostics regions, where the market is poised to increase due to rising healthcare spending and improving healthcare facilities.

Companion Diagnostics Market: Overview

  • Companion diagnostics are biological tests or assays, which aid in predicting the clinical effectiveness or safety of the therapeutic intervention administered to diseased individuals. These diagnostic tests assist physicians in taking effective treatment decisions by elucidating the efficacy of a specific drug prescribed for a specific target population. For instance, Herceptin (trastuzumab), is a monoclonal antibody treatment prescribed for treating breast cancer patients who contain one or more copies of the HER2 gene.
  • Companion diagnostics hold significant growth potential in the near future, owing to several tests in the pipeline. The major advantage associated with the use of companion diagnostics is that it aids in predicting whether a patient will respond to a particular therapy and improves patient outcomes, thereby reducing overall healthcare costs. Other advantages include the ruling out of generic therapies, thereby preventing side effects and resultant hospitalizations.

Companion Diagnostics Market: Key Drivers

  • Technological advancements, higher prevalence of cancer across the globe, research & development activities, drug development, demand for personalized medicines, expansion of the pharmaceutical industry, key mergers & acquisitions, and impact of COVID-19 on companion diagnostics are projected to boost the growth of the global market during the forecast period. A rise in the prevalence and incidence of various infectious diseases such as HIV would attract advanced companion diagnostics, which is likely to propel the global companion diagnostics business during the forecast period. Breast cancer affects one in eight women in their lifetime, and the number of breast cancer cases is rising consistently both in developing and developed countries. According to research, breast cancer is considered the most prevalent cancer in the U.S. According to Breast Cancer Statistics, 287,850 breast cancer cases are expected to be diagnosed in women in 2022. This is likely to augment the global market.
  • Major risk factors for cancer are heredity, aging, obesity, high alcohol consumption, hormone replacement therapy, and cosmetic implants. Technological advancements leading to fast approval of companion diagnostic tests/assays are projected to drive the global market in the next few years. According to research, in 2020, around 44 CDx assays were approved by the FDA. Hence, regulatory approvals for CDx assays across countries are anticipated to propel the global market during the forecast period.

Market Segmentation:

  • In terms of indication, the global market has been classified into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others (HIV and thalassemia)
  • The breast cancer segment accounted for the largest market share in 2020 and the trend is expected to continue during the forecast period. The rise in the prevalence of breast cancer among middle-aged women across the globe and the surge in awareness about the early diagnosis of breast cancer is likely to augment the segment in the next few years. Prostate, lung, and colorectal cancer are the most common cancers diagnosed in men and accounted for 40% of the cases. In women, breast, lung, and colorectal cancer accounts for more than 50% of cancer cases.
  • In 2020, around 2.3 million women were diagnosed with breast cancer, and 685,000 deaths were reported globally in the same year. Breast cancer is considered the most prevalent cancer across the globe. This drives the need for companion diagnostics. According to GLOBOCAN data, globally, new lung cancer accounted for 2.2 million total cancer cases in 2021. Hence, an increase in the incidence of cancer across the globe is projected to drive the need for companion diagnostics during the forecast period.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The companion diagnostics market report provides current and expected revenue (US Mn) for each of these segments from 2021 to 2028, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2028 along with market size estimations.

Regional Overview: Companion Diagnostics Market

  • North America accounted for the largest share of the global market for companion diagnostics in 2020 and the trend is projected to continue during the forecast period. Technological advancements, an increase in patient population, and a rise in the prevalence & incidence rate of cancer are anticipated to drive the market in the region during the forecast period. According to National Cancer statistics, 1,806,590 new cancer cases were diagnosed in the U.S. in 2020, and 606,520 people succumbed to the disease. This is expected to propel the need for companion diagnostics in North America.
  • The market in Asia Pacific is likely to grow at a rapid pace in the next few years, owing to the rise in prevalence and incidence rates of cancer in several countries, the outbreak of the COVID-19 pandemic, and innovation & growth in advanced diagnostic products. An increase in cases of breast cancer is projected to drive the companion diagnostics market in the region. A surge in demand for personalized medicines is anticipated to propel the market in Asia Pacific. Untapped potential, several avenues of scientific research, positive economic growth, ever-increasing population, and positive regulatory scenario for healthcare in high-growth countries attract leading global players to the region.

Major Players

  • The companion diagnostics market report concludes with the company profiles section, which includes key information about major players in the global companion diagnostics business
  • Leading players analyzed in the report include
    • Labcorp Drug Development
    • Agilent Technologies
    • Myriad Genetic Laboratories, Inc.
    • Qiagen
    • Roche Molecular Systems, Inc.
    • Dako, Inc.
    • Abbott
    • Foundation Medicine, Inc.
    • MolecularMD Corporation
    • Ventana Medical Systems, Inc.
    • Illumina, Inc.
    • Life Technologies Corporation
    • Invivoscribe Technologies, Inc.
    • ARUP Laboratories, Inc.
    • Leica Biosystems
    • Biogenex Laboratories, Inc.
    • bioMérieux, Inc.
    • GE Healthcare
    • Agendia N.V
    • Exact Sciences Corp
    • Genomic Health
  • Each of these players has been profiled in the companion diagnostics market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Market Snapshot

Attribute Detail
Market Size Value in 2020 US$ 5.24 Bn
Market Forecast Value in 2028 US$ 9.30 Bn
Growth Rate (CAGR) 9%
Forecast Period 2021-2028
Quantitative Units US$ Mn for Value
Market Analysis It includes cross-segment and regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.
Competition Landscape
  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • By Indication
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Melanoma
    • Others (HIV, Thalassemia)
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa
Companies Profiled
  • Labcorp Drug Development
  • Agilent Technologies
  • Myriad Genetic Laboratories, Inc.
  • Qiagen
  • Roche Molecular Systems, Inc.
  • Dako, Inc.
  • Abbott
  • Foundation Medicine, Inc.
  • MolecularMD Corporation
  • Ventana Medical Systems, Inc.
  • Illumina, Inc.
  • Life Technologies Corporation
  • Invivoscribe Technologies, Inc.
  • ARUP Laboratories, Inc.
  • Leica Biosystems
  • Biogenex Laboratories, Inc.
  • bioMérieux, Inc.
  • GE Healthcare
  • Agendia N.V
  • Exact Sciences Corp
  • Genomic Health
Customization Scope Available upon request
Pricing Available upon request

Companion Diagnostics Market - Segmentation

Attribute Detail
Indication
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Melanoma
  • Others (HIV, Thalassemia)
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of companion diagnostics market?

The global market for companion diagnostics is expected to reach the value of US$ 9.30 Bn by the end of 2028

What is the anticipated CAGR of the companion diagnostics industry in the forecast period?

The companion diagnostics market is estimated to expand at a CAGR of 9% from 2021 to 2028

What are the key driving factors for the growth of the global market for companion diagnostics?

The companion diagnostics market is driven by an increase in demand and the development of personalized medicine

Which is the rising prominent segment in the global market for companion diagnostics?

The breast cancer segment accounted for the largest market share in 2020 and the trend is expected to continue during the forecast period.

Who are the key players in the global companion diagnostics business?

Key players operating in the market are Labcorp Drug Development, Agilent Technologies, Myriad Genetic Laboratories, Inc., Qiagen, Roche Molecular Systems, Inc., Dako, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Companion Diagnostics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Companion Diagnostics Market Analysis and Forecast, 2017-2028

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Recent Approval of Companion Diagnostics for Cancer Care

        5.2. Disease Prevalence & Incidence rate of Cancer

        5.3. Key Mergers & Acquisitions

        5.4. Regulatory Scenarios across globe

        5.5. Overview of Personalized Medicine

        5.6. Porters Five Forces Analysis

        5.7. COVID-19 pandemic impact on the Global Companion Diagnostics Market

    6. Global Companion Diagnostics Market Analysis and Forecast, by Indication

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type, 2017-2028

            6.3.1. Breast Cancer

            6.3.2. Lung Cancer

            6.3.3. Colorectal Cancer

            6.3.4. Gastric Cancer

            6.3.5. Melanoma

            6.3.6. Others (HIV, Thalassemia)

        6.4. Market Attractiveness Analysis, by Type

    7. Global Companion Diagnostics Market Analysis and Forecast, by Region

        7.1. Key Findings

        7.2. Market Value Forecast, by Region

            7.2.1. North America

            7.2.2. Europe

            7.2.3. Asia Pacific

            7.2.4. Latin America

            7.2.5. Middle East & Africa

        7.3. Market Attractiveness Analysis, by Region

    8. North America Companion Diagnostics Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. Market Value Forecast, by Type, 2017-2028

            8.2.1. Breast Cancer

            8.2.2. Lung Cancer

            8.2.3. Colorectal Cancer

            8.2.4. Gastric Cancer

            8.2.5. Melanoma

            8.2.6. Others (HIV, Thalassemia)

        8.3. Market Value Forecast, by Country, 2017-2028

            8.3.1. U.S.

            8.3.2. Canada

        8.4. Market Attractiveness Analysis

            8.4.1. By Indication

            8.4.2. By Country

    9. Europe Companion Diagnostics Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Type, 2017-2028

            9.2.1. Breast Cancer

            9.2.2. Lung Cancer

            9.2.3. Colorectal Cancer

            9.2.4. Gastric Cancer

            9.2.5. Melanoma

            9.2.6. Others (HIV, Thalassemia)

        9.3. Market Value Forecast, by Country/Sub-region, 2017-2028

            9.3.1. Germany

            9.3.2. U.K.

            9.3.3. France

            9.3.4. Italy

            9.3.5. Spain

            9.3.6. Rest of Europe

        9.4. Market Attractiveness Analysis

            9.4.1. By Indication

            9.4.2. By Country/Sub-region

    10. Asia Pacific Companion Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Type, 2017-2028

            10.2.1. Breast Cancer

            10.2.2. Lung Cancer

            10.2.3. Colorectal Cancer

            10.2.4. Gastric Cancer

            10.2.5. Melanoma

            10.2.6. Others (HIV, Thalassemia)

        10.3. Market Value Forecast, by Country/Sub-region, 2017-2028

            10.3.1. Japan

            10.3.2. China

            10.3.3. India

            10.3.4. Australia & New Zealand

            10.3.5. Rest of Asia Pacific

        10.4. Market Attractiveness Analysis

            10.4.1. By Indication

            10.4.2. By Country/Sub-region

    11. Latin America Companion Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017-2028

            11.2.1. Breast Cancer

            11.2.2. Lung Cancer

            11.2.3. Colorectal Cancer

            11.2.4. Gastric Cancer

            11.2.5. Melanoma

            11.2.6. Others (HIV, Thalassemia)

        11.3. Market Value Forecast, by Country/Sub-region, 2017-2028

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.3. Rest of Latin America

        11.4. Market Attractiveness Analysis

            11.4.1. By Indication

            11.4.2. By Country/Sub-region

    12. Middle East & Africa Companion Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type, 2017-2028

            12.2.1. Breast Cancer

            12.2.2. Lung Cancer

            12.2.3. Colorectal Cancer

            12.2.4. Gastric Cancer

            12.2.5. Melanoma

            12.2.6. Others (HIV, Thalassemia)

        12.3. Market Value Forecast, by Country/Sub-region, 2017-2028

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.3. Rest of Middle East & Africa

        12.4. Market Attractiveness Analysis

            12.4.1. By Indication

            12.4.2. By Country/Sub-region

    13. Competition Landscape

        13.1. Market Player - Competition Matrix (by tier and size of companies)

        13.2. Market Share Analysis, by Company, 2020

        13.3. Company Profiles

            13.3.1. Labcorp Drug Development

                13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.1.2. Financial Overview

                13.3.1.3. Product Portfolio

                13.3.1.4. Strategic Overview

                13.3.1.5. SWOT Analysis

            13.3.2. Agilent Technologies

                13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.2.2. Financial Overview

                13.3.2.3. Product Portfolio

                13.3.2.4. Strategic Overview

                13.3.2.5. SWOT Analysis

            13.3.3. Myriad Genetic Laboratories, Inc.

                13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.3.2. Financial Overview

                13.3.3.3. Product Portfolio

                13.3.3.4. Strategic Overview

                13.3.3.5. SWOT Analysis

            13.3.4. Qiagen

                13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.4.2. Financial Overview

                13.3.4.3. Product Portfolio

                13.3.4.4. Strategic Overview

                13.3.4.5. SWOT Analysis

            13.3.5. Roche Molecular Systems, Inc.

                13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.5.2. Financial Overview

                13.3.5.3. Product Portfolio

                13.3.5.4. Strategic Overview

                13.3.5.5. SWOT Analysis

            13.3.6. Dako Inc.

                13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.6.2. Financial Overview

                13.3.6.3. Product Portfolio

                13.3.6.4. Strategic Overview

                13.3.6.5. SWOT Analysis

            13.3.7. Abbott

                13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.7.2. Financial Overview

                13.3.7.3. Product Portfolio

                13.3.7.4. Strategic Overview

                13.3.7.5. SWOT Analysis

            13.3.8. Foundation Medicine, Inc.

                13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.8.2. Financial Overview

                13.3.8.3. Product Portfolio

                13.3.8.4. Strategic Overview

                13.3.8.5. SWOT Analysis

            13.3.9. MolecularMD Corporation

                13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.9.2. Financial Overview

                13.3.9.3. Product Portfolio

                13.3.9.4. Strategic Overview

                13.3.9.5. SWOT Analysis

            13.3.10. Ventana Medical Systems, Inc.

                13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.10.2. Product Portfolio

                13.3.10.3. Strategic Overview

            13.3.11. Illumina, Inc.

                13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.11.2. Product Portfolio

                13.3.11.3. Strategic Overview

                13.3.11.4. SWOT Analysis

            13.3.12. Life Technologies Corporation

                13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.12.2. Product Portfolio

                13.3.12.3. Strategic Overview

                13.3.12.4. SWOT Analysis

            13.3.13. Invivoscribe Technologies, Inc.

                13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.13.2. Product Portfolio

                13.3.13.3. Strategic Overview

                13.3.13.4. SWOT Analysis

            13.3.14. ARUP Laboratories, Inc.

                13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.14.2. Product Portfolio

                13.3.14.3. Strategic Overview

                13.3.14.4. SWOT Analysis

            13.3.15. Leica Biosystems

                13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.15.2. Product Portfolio

                13.3.15.3. Strategic Overview

                13.3.15.4. SWOT Analysis

            13.3.16. Biogenex Laboratories, Inc.

                13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.16.2. Product Portfolio

                13.3.16.3. Strategic Overview

                13.3.16.4. SWOT Analysis

            13.3.17. bioMérieux, Inc.

                13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.17.2. Product Portfolio

                13.3.17.3. Strategic Overview

                13.3.17.4. SWOT Analysis

            13.3.18. GE Healthcare

                13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.18.2. Product Portfolio

                13.3.18.3. Strategic Overview

                13.3.18.4. SWOT Analysis

            13.3.19. Agendia N.V

                13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.19.2. Product Portfolio

                13.3.19.3. Strategic Overview

                13.3.19.4. SWOT Analysis

            13.3.20. Exact Sciences Corp

                13.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.20.2. Product Portfolio

                13.3.20.3. Strategic Overview

                13.3.20.4. SWOT Analysis

            13.3.21. Genomic Health

                13.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.21.2. Product Portfolio

                13.3.21.3. Strategic Overview

                13.3.21.4. SWOT Analysis

    List of Tables

    Table 01: Global Companion Diagnostics Value (US$ Mn) Forecast, by Indication, 2017-2028

    Table 02: Global Companion Diagnostics Value (US$ Mn) Forecast, by Region, 2017-2028

    Table 03: North America Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017-2028

    Table 04: North America Companion Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2028

    Table 05: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017-2028

    Table 06: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028

    Table 07: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017-2028

    Table 08: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028

    Table 09: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017-2028

    Table 10: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028

    Table 11: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017-2028

    Table 12: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028

    List of Figures

    Figure 01: Global Companion Diagnostics Market Value (US$ Mn) Forecast, 2017-2028

    Figure 02: Global Companion Diagnostics Market Value Share, by Indication, 2020

    Figure 03: Global Companion Diagnostics Market Value Share, by Region, 2020

    Figure 04: Global Companion Diagnostics Value Share Analysis, by Indication, 2020 and 2028

    Figure 05: Global Companion Diagnostics Attractiveness Analysis, by Indication, 2021-2028

    Figure 06: Global Companion Diagnostics Market Value (US$ Mn), by Breast Cancer, 2017-2028

    Figure 07: Global Companion Diagnostics Market Value (US$ Mn), by Lung Cancer, 2017-2028

    Figure 08: Global Companion Diagnostics Market Value (US$ Mn), by Colorectal Cancer, 2017-2028

    Figure 09: Global Companion Diagnostics Market Value (US$ Mn), by Gastric Cancer, 2017-2028

    Figure 10: Global Companion Diagnostics Market Value (US$ Mn), by Melanoma, 2017-2028

    Figure 11: Global Companion Diagnostics Market Value (US$ Mn), by Others, 2017-2028

    Figure 12: Global Companion Diagnostics Value Share Analysis, by Region, 2020 and 2028

    Figure 13: Global Companion Diagnostics Attractiveness Analysis, by Region, 2021-2028

    Figure 14: Global Companion Diagnostics Market Value (US$ Mn), by North America, 2017-2028

    Figure 15: Global Companion Diagnostics Market Value (US$ Mn), by Europe, 2017-2028

    Figure 16: Global Companion Diagnostics Market Value (US$ Mn), by Asia Pacific, 2017-2028

    Figure 17: Global Companion Diagnostics Market Value (US$ Mn), by Latin America, 2017-2028

    Figure 18: Global Companion Diagnostics Market Value (US$ Mn), by Middle East & Africa, 2017-2028

    Figure 19: North America Companion Diagnostics Market Value (US$ Mn) Forecast, 2017-2028

    Figure 20: North America Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 21: North America Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 22: North America Companion Diagnostics Value Share Analysis, by Country, 2020 and 2028

    Figure 23: North America Companion Diagnostics Attractiveness Analysis, by Country, 2021-2028

    Figure 24: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, 2017-2028

    Figure 25: Europe Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 26: Europe Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 27: Europe Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 28: Europe Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021-2028

    Figure 29: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, 2017-2028

    Figure 30: Asia Pacific Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 31: Asia Pacific Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 32: Asia Pacific Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 33: Asia Pacific Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021-2028

    Figure 34: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, 2017-2028

    Figure 35: Latin America Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 36: Latin America Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 37: Latin America Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 38: Latin America Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021-2028

    Figure 39: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, 2017-2028

    Figure 40: Middle East & Africa Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 41: Middle East & Africa Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 42: Middle East & Africa Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 43: Middle East & Africa Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021-2028

    Figure 44: Global Companion Diagnostics Market Share Analysis, by Company, 2020

Copyright © Transparency Market Research, Inc. All Rights reserved